Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD

摘要: Objective: To investigate whether polymorphisms in the genes for dopamine receptors D 1 and 2 are associated with risk of developing peak-dose dyskinesias PD. Background: Peak-dose most common side effects levodopa therapy The identified predictors may only partially account because a substantial proportion patients never develop dyskinesias. Genetic factors could play role determining occurrence Methods: A case-control study 136 subjects sporadic PD 224 population control subjects. We studied three involving receptor gene one intronic short tandem repeat polymorphism gene. Results: were not or 15 allele was more frequent parkinsonian than More important, frequency both 13 14 higher nondyskinetic dyskinetic reduction carrying at least alleles 72% respect to who did carry these alleles. Conclusions: Certain reduce contribute varying susceptibility during therapy.